Market Place
Sourcing Support
All News #Library
Biotech
Propanc Pharma Targets $3B+ Pancreatic Cancer Market With PRP
12 Mar 2026 //
GLOBENEWSWIRE
Propanc Bio Partners FyoniBio For Phase 1B Pk Assay Validation
10 Mar 2026 //
GLOBENEWSWIRE
Propanc Bio`s PRP Achieves >85% Tumor Growth Inhibition in Model
03 Mar 2026 //
GLOBENEWSWIRE
Propanc Unveils PRP Proenzyme Therapy Targeting Pancreatic Cancer
05 Feb 2026 //
GLOBENEWSWIRE
Propanc Bio Files Patent For Trypsinogen & Chymotrypsinogen
20 Jan 2026 //
GLOBENEWSWIRE
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
15 Jan 2026 //
GLOBENEWSWIRE
Propanc Targets Mesenchymal Drift to Reverse Chronic Cancers
04 Dec 2025 //
GLOBENEWSWIRE
Propanc Bio Seeks Spanish License For Treating Resistant Cancer
01 Dec 2025 //
GLOBENEWSWIRE
Propanc Bio Secures $100M For Digital Asset Acquisition & R&D
10 Nov 2025 //
GLOBENEWSWIRE
Propanc Biopharma Granted `Proenzyme Composition` Patent by USPTO
17 Sep 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.